Clinical trial · Observational

Significance of Benign Lymph Node Enlargement in Colorectal Cancer

NCT06410729CI-TRIAL-00077125completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The objective of this observational study was to investigate the clinical significance of benign mesenteric lymph node （BLNE） enlargement in patients with colorectal cancer. The main questions it aims to answer are: Do patients with benign mesenteric lymph node enlargement have a better prognosis? What are the clinical characteristics of benign mesenteric lymph node enlargement? As part of routine medical care for colorectal cancer, we will follow up with all participants over the course of the study.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Colorectal Neoplasms Malignant	Colon Neoplasm	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Observational study, no intervention	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (3)

label
Benign mesenteric lymph node enlargement (BLNE)
description
Lymph nodes with a diameter \> 8 mm on preoperative imaging without metastasis on postoperative pathology were termed benign mesenteric lymph node enlargement.
interventionNames
1. Other: Observational study, no intervention
label
Non-benign mesenteric lymph node enlargement (NBLNE)
description
Lymph nodes with a diameter \< 8 mm on preoperative imaging without metastasis on postoperative pathology were termed non-benign mesenteric lymph node enlargement.
interventionNames
1. Other: Observational study, no intervention
label
Metastatic mesenteric lymph node enlargement (MLNE)
description
Lymph nodes with a diameter \> 8 mm on preoperative imaging with metastasis on postoperative pathology were termed metastatic mesenteric lymph node enlargement .
interventionNames

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* no regional lymph node metastasis or distant metastasis;
* stage I and II patients in the AJCC staging system;
* radical CRC resection achieving R0 status with no positive lymph nodes;
* a single malignant lesion confirmed via colonoscopy

Exclusion Criteria:

* underwent emergency surgery or had preoperative complications such as intestinal obstruction or perforation;
* had suspected distant metastasis on positron emission tomography (PET-CT);
* received preoperative neoadjuvant therapy;
* had hereditary CRC such as familial adenomatous polyposis;
* had microsatellite instability (MSI) confirmed by pathology.
* lacked imaging data;
* were lost to follow-up.

References

Publications (0)

Data not yet available

No reference posted for this study.